DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Novel adcs and strategies to overcome resistance to anti-her2 adcs
During recent years, a number of new compounds against HER2 have reached clinics, improving the prognosis and quality of life of HER2-positive breast cancer patients. Nonetheless, resistance to standard-of-care drugs has motivated the development of novel agents, such as new antibody-drug conjugates (ADCs). The latter are a group of drugs that benefit from the potency of cytotoxic agents whose action is specifically guided to the tumor by the target-specific antibody. Two anti-HER2 ADCs have reached the clinic: trastuzumab-emtansine and, more recently, trastuzumab-deruxtecan. In addition, several other HER2-targeted ADCs are in preclinical or clinical development, some of them with promising signs of activity. In the present review, the structure, mechanism of action, and potential resistance to all these ADCs will be described. Specific attention will be given to discussing novel strategies to circumvent resistance to ADCs., This work was supported by grants from the Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R and PID2020-115605RB-I00), the Instituto de Salud Carlos III through CIBERONC, Junta de Castilla y León (CSI146P20), ALMOM, ACMUMA, UCCTA and the CRIS Cancer Foundation (A.P.), and by the Instituto de Salud Carlos III (PI19/00808), ACEPAIN, and CRIS Cancer Foundation (A.O.). Work carried out in A.P.’s and A.O.’s laboratories received support from the European Community through the Regional Development Funding Program (FEDER). L.G.-S. was the recipient of a predoctoral contract (BES-2016-077748) and is presently contracted with the Cancer Research Foundation of Salamanca University (FICUS).